The Longevity Digest 02/03 - 02/09
I'm cutting through the noise in longevity and anti-aging podcasts so you don't have to.
Welcome to The Longevity Digest.
The field moves fast. Too fast for most of us to track every breakthrough, every protocol update, every researcher’s latest findings. That’s where this comes in.
I’ve curated specific shows that consistently deliver evidence-based insights you can actually use. Think less fluff, more substance. The kind of information that changes how you practice or how you live.
Got a podcast that’s been delivering gold? Send it my way. I’m always hunting for voices that push the field forward.
This Newsletter Is Sponsored By Casa de Sante.
Dr Onyx MD PhD’s Insights on this week’s episodes
The Inflammation Axis: From Ancient Spices to Next-Gen Cardiology, One Pathway Dominates
If a single theme united this week’s airwaves, it was this: chronic, low-grade inflammation — “inflammaging” — is not a background hum of getting older. It is the operating system of decline, and virtually every conversation circled back to shutting it down.
On Health Longevity Secrets, Dr. Shivani Gupta made the case that Ayurveda identified the problem centuries before molecular biology named it. Her practical translation — standardized curcumin (~1,000 mg curcuminoids/day with piperine), circadian-aligned sleep, and gut-centered nutrition — targets the same NF-κB/TNF-α/IL-6 cascade that modern geroscience considers central to age-related disease. The evidence base for curcumin is real, if still underweight on randomized trials: a 2021 meta-analysis showed meaningful CRP reductions at these doses, especially in autoimmune-driven inflammation. The caveat she rightly flagged — screen for anticoagulants, iron deficiency, and oxalate risk — is the kind of precision that separates a useful adjunct from a supplement aisle impulse buy.
But zoom out, and the inflammation thread ran far beyond botanicals. On This Week in Cardiology, the clinical stakes sharpened considerably. The PREVENT risk calculator — designed to be race-neutral — was shown to underestimate 10-year CVD risk in young non-Hispanic Black adults by roughly 46%, and layering on a social-determinants index didn’t fix it. That’s not an academic footnote; it’s an algorithmic blind spot that can delay statin or antihypertensive initiation precisely when early prevention matters most. Meanwhile, the OCEANIC-STROKE data (Factor XI inhibitor asundexian added to antiplatelets) delivered a 26% reduction in recurrent ischemic stroke with no bleeding penalty — a signal that targeting coagulation’s inflammatory-thrombotic interface may be the next frontier. And the large CTT meta-analysis of 66 statin RCTs quietly demolished the myth of widespread statin harm: 62 of 66 alleged adverse events showed no excess risk, with the SAMSON trial reinforcing that most “statin intolerance” is nocebo-driven. For the busy clinician, the takeaway is blunt: under-treating inflammation-linked cardiovascular risk — whether through flawed algorithms or unfounded statin fears — likely costs more lives than any supplement can save.
The strategic implication is clear. Inflammation is not one problem with one solution. It is a multi-scale challenge demanding multi-scale responses: curcumin and circadian hygiene at the lifestyle layer, statins and novel anticoagulants at the pharmacotherapy layer, and better risk algorithms at the systems layer. The clinicians and executives who grasp that hierarchy — and invest accordingly — will lead the next decade of preventive care.
This Newsletter Is Sponsored By Casa de Sante.
For anyone on GLP-1 medications like Ozempic or Wegovy, Low FODMAP nutrition is non-negotiable. These medications can slow digestion and trigger bloating or nausea, so choosing gut-friendly products helps you stay comfortable while protecting muscle and metabolism. Physician-formulated by Dr Onyx MD PhD Certified in Obesity Management, this Low FODMAP lineup supports nutrient absorption, muscle defense, and overall digestive balance:
Premium Protein Powder (Vegan Vanilla, Whey Vanilla, or Whey Chocolate) – helps preserve lean muscle during weight loss
FODMAP Digestive Enzymes – improves absorption and reduces GI side effects
Advanced Probiotic + Prebiotic Synbiotic Formula – supports a balanced gut microbiome
Essential Vitamin & Mineral Complex – replenishes nutrients often depleted during rapid weight loss
Gentle Colon Cleanse + Probiotic Support – aids regular elimination without irritation
All formulas are low FODMAP, non-GMO, and third-party tested—the ideal foundation for GLP-1 users focused on digestive comfort, metabolic health, and muscle preservation.
Because hormones and skin health are deeply connected, Dr Onyx MD PhD science-backed skincare supports barrier repair, hydration, and inflammation balance for healthy, resilient skin—especially during menopause or while using GLP-1 medications, when collagen loss and dryness can accelerate:
HydraLift Collagen Complex – firms and smooths for youthful elasticity
Antioxidant C+E Ferulic Radiance Serum – brightens and defends against oxidative stress
Needle-Free Wrinkle Smoother – softens fine lines without irritation
Ultra Retinol 10x + Bakuchiol Serum – boosts cell turnover with gentle plant retinol
Advanced Retinol Eye Repair – targets puffiness and under-eye wrinkles
Cellular Repair Growth Factor Peptides Serum – rejuvenates and supports skin repair
Advanced Neck Lift Firming Complex – improves tone and texture along the jawline and neck
Even Tone Brightening Cream – evens discoloration for radiant, balanced skin
The Repair Economy: Fasting, Stem Cells, Mitophagy, and the Race to Rebuild
A second, equally powerful current this week was the shift from merely slowing damage to actively reversing it — what might be called the emerging “repair economy” of longevity medicine.
Dr. Valter Longo, on The Human Upgrade (Episode 1409), laid out the most evidence-dense framework: periodic fasting-mimicking diet (FMD) cycles — roughly five days, three to four times a year — combined with a 12-hour eating window and plant-forward protein (~0.8 g/kg/day). The mechanism is elegant: suppress insulin/IGF-1/mTOR long enough to trigger genuine autophagy (typically after ~5 days), then refeed to activate stem-cell-driven tissue rebuilding. Longo’s key nuance is often missed — it’s not chronic restriction that works, but the alternation between low and high anabolic states. He also issued a pointed warning that diet quality may outperform GLP-1 agonists for long-term cardiometabolic protection, a claim that will gain traction as generic semaglutide reshapes access (more on that below).
Two days later, Episode 1410 of the same show pushed the repair thesis deeper into biology: stem cell exhaustion as a core hallmark of aging. The argument — that red marrow converts to fatty marrow with age, depleting circulating stem cells and impairing tissue repair — reframes chronic inflammation not just as a cause of damage, but as a signal of inadequate repair. The practical prescription: a medically supervised 72-hour fast, twice yearly, to rejuvenate hematopoietic stem cells via autophagy, stacked with microcirculation and mitochondrial support. Whether endogenous mobilization via plant extracts can meaningfully supplement this (as the episode’s commercial segment suggested) remains an open question — the peer-reviewed data is thin, and the pulmonary first-pass problem with IV stem cells is well-documented.
Then Episode 1412 zoomed into the mitochondrial engine room. The thesis: after 40, it’s not just that mitochondria decline — it’s that the quality-control system (mitophagy) fails. Urolithin A, a gut-microbiome-derived metabolite that only 30–40% of people produce naturally, was positioned as a direct mitophagy activator, with branded claims of ~40% increased mitochondrial renewal and ~12% muscle strength gains over 16 weeks. The science is early-stage but mechanistically sound; the conflict-of-interest disclosure (paid endorsement) is material. The real clinical pearl is the protocol framework around it: twice-weekly resistance training, adequate protein (1.0–1.2 g/kg/day), and optimized sleep form the non-negotiable foundation. Urolithin A, if anything, is the optional accelerant — never the substitute.
Even Ido Portal’s conversation on the Huberman Lab — ostensibly about movement philosophy, not molecular biology — reinforced the repair theme from a different angle. His emphasis on training sensory levers (panoramic vs. focal gaze, peripersonal space tolerance) to regulate autonomic arousal is, at its core, about restoring the nervous system’s adaptive capacity — the movement equivalent of cellular repair. For clinicians working with anxious, deconditioned, or post-injury patients, the actionable gem is simple: alternate 60–90 seconds of soft-gaze panoramic awareness with narrow focus during walks or light resistance work. It costs nothing, requires no supplement, and directly modulates the sympathetic–parasympathetic balance that feeds systemic inflammation.
The emerging trend is unmistakable. Longevity science is pivoting from a “slow the decline” paradigm to a “rebuild the machinery” paradigm — fasting to trigger autophagy and stem-cell renewal, urolithin A to rescue mitophagy, movement to restore neuroplasticity. The shared logic: the body already has repair systems. The job of longevity medicine is to unblock them.
GLP-1s, Peptides, and the Access Revolution: Power Tools Demand Power Protocols
The third theme this week was pharmacological — and it carried a warning. As GLP-1 receptor agonists move from niche diabetes drugs to mainstream metabolic tools (and now, potentially, addiction medicine), the field is grappling with a critical question: access without infrastructure is harm.
On The Second Opinion Podcast, Dr. Paul Kolodzik described a pragmatic, harm-reduction approach to alcohol use disorder: combine a GLP-1 agonist with targeted naltrexone (taken on drinking days) and simple behavioral tracking. Patients report becoming “disinterested” in alcohol, with anecdotal intake reductions of 60–70%. Observational signals extend to nicotine, with formal trials underway. The clinical logic — attenuating central reward pathways pharmacologically while building behavioral scaffolding — is sound, and the emphasis on harm reduction over mandatory abstinence reflects where addiction medicine is heading.
But Episode 1411 of The Human Upgrade raised the stakes: India’s move toward generic semaglutide could blow the doors open on global GLP-1 access. That’s a net positive for public health — until you consider what happens when millions of patients lose weight rapidly without muscle-preservation protocols. The episode’s warning was direct: pair every GLP-1 prescription with resistance training (2–3 sessions/week with progressive overload), adequate protein (1.2–1.6 g/kg/day, adjusted for renal status), and body-composition monitoring (DEXA or BIA at baseline and 3–6 months). The same message echoed on The Pro-Aging Podcast, where Dr. Jake Deutsch laid out a broader peptide framework — GLP-1s as the “anchor” of metabolic optimization, but always paired with lean-mass protection, reputable sourcing, and interval labs (CBC, CMP, A1c, lipids, IGF-1 as indicated). His strongest caution: avoid unsupervised multi-peptide “stacks,” introduce one agent at a time from a reputable pharmacy, and cycle GH secretagogues to prevent receptor downregulation.
Even the behavioral-genetics conversation on Huberman Lab with Dr. Kathryn Paige Harden connected to this theme — from a different direction. Her work showing that addiction, impulsive aggression, and risky behavior share a broad polygenic architecture active during fetal cortical development reframes substance use disorders as neurodevelopmental conditions. The practical implication: screen adolescents early for externalizing traits, use reward-based (not punitive) strategies, and recognize that polygenic scores are not yet clinically actionable at the individual level. For clinicians prescribing GLP-1s or naltrexone for addiction, understanding this neurodevelopmental substrate underscores why pharmacotherapy works best within a structured behavioral and monitoring framework — not as a standalone fix.
The strategic signal for executives and clinicians alike: the pharmacological toolkit for metabolic and addictive disease is expanding faster than the clinical infrastructure to support it. Generic GLP-1s, off-label peptide therapies, and novel harm-reduction protocols are powerful — but only when embedded in systems that monitor body composition, protect lean mass, ensure reputable sourcing, and personalize dosing. The winners in this next phase won’t be the fastest prescribers. They’ll be the ones who build the protocols around the prescriptions.
This weeks episodes:
1. Health Longevity Secrets
Ancient Health Secret Revealed with Dr Shivani Gupta
Published: 2026-02-03
URL: Listen Here
Summary
Dr. Shivani Gupta bridges Ayurvedic principles with contemporary science to address chronic inflammation as a reversible driver of aging and disease. The episode offers clinicians practical daily routines and evidence-informed use of spices—especially curcumin—to complement standard management of inflammatory and metabolic conditions; no specific randomized trials were cited during the discussion.
Key Takeaways
Ayurveda’s core pillars—circadian alignment, gut-centered nutrition, stress regulation, and gentle detox rituals—map closely to modern concepts of metabolic health and can mitigate ‘inflammaging.’
Chronic low-grade inflammation often presents as joint aches, brain fog, fatigue, weight gain, and poor sleep; reframing these as modifiable inflammation rather than ‘normal aging’ enables targeted lifestyle and adjunctive therapies.
Curcumin/turmeric exhibits broad anti-inflammatory and antioxidant effects (e.g., NF-κB, TNF-α, IL-6, sirtuins, AMPK) with potential neuro- and mito-support; however, consider contraindications (anticoagulants, low iron, kidney stone history).
Practical Ayurvedic routines include morning intention, hydration, copper tongue-scraping, oil pulling, and early daylight exposure; evening practices such as dry brushing, abhyanga oil massage, Epsom salt baths, and sleep hygiene support recovery.
Midlife women may benefit from prioritizing sleep (particularly the 10 pm–2 am window), evaluation of progesterone, and adaptogens (e.g., ashwagandha, shatavari, bacopa); super-spices can augment anti-inflammatory dietary patterns.
Clinical Insight
Inflammaging underlies much of chronic disease burden, and integrating circadian-aligned lifestyle medicine with targeted botanicals—especially standardized curcumin—can meaningfully reduce symptom load and biological aging alongside conventional care.
Actionable Takeaway
Trial a 2–4 week adjunct of standardized curcumin providing ~1,000 mg curcuminoids/day (taken with piperine or a healthy fat) plus strict sleep timing (lights out by ~10 pm); screen for anticoagulant use, iron deficiency, and kidney stone history before initiating.
2. The Human Upgrade: Biohacking for Longevity & Performance
STOP Intermittent Fasting If You Want to Stay Young : 1409
Published: 2026-02-03
URL: Listen Here
Summary
Dr. Valter Longo explains how periodic fasting-mimicking diets, combined with circadian-aligned eating and lower essential amino acid intake, downregulate insulin/IGF-1/mTOR pathways to drive autophagy, stem-cell activation, and tissue rejuvenation while preserving lean mass. He emphasizes alternating fasting and refeeding, carefully dosing fasting in lean/older patients, and prioritizing multi-pillar evidence (human cohorts, clinical trials, animal models, centenarians) over short-term outcomes or single-mechanism interventions.
Key Takeaways
Short-term benefits do not guarantee long-term health or longevity; across a century of data, lower protein—especially lower essential amino acids like methionine and leucine—is consistently linked to longer lifespan in animal models, while high animal protein intake is associated with higher risks of diabetes, obesity, cardiovascular mortality, and some cancers in human cohorts.
Periodic fasting-mimicking diet (FMD) cycles (about 5 days, 3–4 times/year) combined with a 12-hour daily eating window and lifestyle pillars (exercise, sleep) lower insulin/IGF-1/mTOR signaling, trigger autophagy (often after ~5 days), and promote organ ‘shrink-and-rebuild’ with stem-cell activation and tissue reprogramming, yielding fat loss with preservation of lean mass.
Longevity depends on modulating the growth-hormone/IGF-1/mTOR axis: chronic elevation accelerates aging, whereas alternating low (fasting) and high (refeeding) states supports repair and subsequent rebuilding; the growth hormone receptor is a key master regulator, with mTOR inhibition (e.g., rapamycin) effective even when started late in life in animal models.
Fasting requires dosing and personalization: very lean or older patients may need less frequent/intense fasting; water-only prolonged fasts can increase gut permeability in mice, whereas the FMD is designed to mitigate risks (e.g., includes glycerol and prebiotic components) while maintaining fasting benefits.
Diet quality can outperform weight-loss drugs for long-term cardiometabolic protection (e.g., Mediterranean/longevity diets vs GLP-1s for CVD risk); avoid megadosing supplements without multi-pillar evidence, and personalize potential inflammatory triggers (e.g., oxalates) rather than excluding longevity-promoting foods wholesale.
Clinical Insight
For longevity and healthy function, target the growth-hormone/IGF-1/mTOR axis with periodic, food-based fasting (FMD) and modest predominantly plant-based protein (~0.8 g/kg/day), aiming for alternation between low (fasting) and high (refeeding) anabolic signals and keeping IGF-1 within an optimal range rather than chronically high or low.
Actionable Takeaway
For a middle-aged patient with elevated IGF-1 or central adiposity, consider a 5-day FMD every 3–4 months plus a consistent 12-hour daily eating window, paired with ~0.8 g/kg/day protein emphasizing plant sources; monitor IGF-1 (target roughly 120–160 ng/mL), fasting glucose, and body composition, and reduce fasting frequency for very lean or older patients.
3. The Second Opinion Podcast with Dr. Paul Kolodzik
Exploring GLP-1: A Breakthrough in Reducing Alcohol Dependence with Dr. Paul Kolodzik
Published: 2026-02-05
URL: Listen Here
Summary
This episode discusses emerging use of GLP-1 receptor agonists to reduce alcohol dependence, highlighting a combined approach with naltrexone and basic behavioral tracking to operationalize harm reduction. It offers real-world cases, notes early observational signals (including possible nicotine benefits), and contrasts harm reduction with abstinence, while acknowledging that some guidance and approvals mentioned should be independently verified.
Key Takeaways
GLP-1 receptor agonists (e.g., semaglutide/Ozempic/Wegovy; tirzepatide/Mounjaro/Zepbound) appear to markedly reduce alcohol craving and intake—patients often report becoming “disinterested” in alcohol—with anecdotal reductions of roughly 60–70% and early studies underway.
The “Kolodzik method” combines a GLP-1 RA with targeted naltrexone dosing (taken on drinking days, before alcohol) plus simple behavioral tracking (e.g., drink logs) to support harm reduction rather than mandatory abstinence.
Harm reduction is emphasized as a pragmatic goal for many patients (drinking less rather than none), though abstinence remains appropriate and life-changing for some.
Observational data suggest GLP-1s may also curb nicotine use; formal trials are ongoing to clarify effects beyond alcohol.
The episode asserts recent U.S. public health guidance removed numeric weekly alcohol limits and reiterates prior reference points (≈15/week for men, 7/week for women), but advises that “less is better”; these claims were not sourced in-episode and should be verified.
Clinical Insight
GLP-1 receptor agonists—especially when paired with naltrexone—may provide an effective, medication-assisted harm-reduction strategy for alcohol use disorder by attenuating central reward/craving pathways, enabling substantial and sustainable decreases in alcohol consumption without requiring immediate abstinence.
Actionable Takeaway
For adults with alcohol use disorder who aim to cut down (not necessarily abstain), consider initiating naltrexone (taken prior to anticipated drinking) and, when otherwise indicated for obesity or diabetes, adding a GLP-1 RA off-label; have the patient keep a simple drink log and schedule follow-up in 4 weeks to reassess intake, cravings, side effects, and readiness for further reduction—ensuring contraindications and FDA-approved indications are reviewed.
4. Huberman Lab
Essentials: The Science & Practice of Movement | Ido Portal
Published: 2026-02-05
URL: Listen Here
Summary
This episode with Ido Portal emphasizes movement as a pervasive practice of sensory-driven awareness, exploration, and play rather than a narrow set of exercises. The discussion details how manipulating vision, hearing, posture, and proximity can unlock adaptability, reduce reactivity, and evolve technique toward virtuosity while challenging overly linear training paradigms (including modern yoga). Note: This summary is based on an excerpted transcript and may omit additional context from the full episode.
Key Takeaways
Movement is an open, decentralized practice grounded in awareness of motion across body, mind, and emotions; cultivate nonverbal, playful exploration throughout daily life.
Deliberately train sensory states—especially vision (panoramic vs focused gaze, head/eye posture) and hearing (head/ear orientation)—to modulate arousal, reaction time, and organize movement.
Progress beyond fixed techniques and habitual “postures” in thought, emotion, and movement; embrace variability to move from skill and mastery toward virtuosity.
Systematically explore peripersonal space, touch, and proximity to titrate reactivity, improve clear thinking, and expand social-emotional and motor options.
Challenge linear exercise norms (e.g., modern yoga, machine-based lifting) by varying stance, breath, head/eye position, and context; favor inquiry and play over rigid “hacks.”
Clinical Insight
Training sensory levers—particularly visual state (panoramic vs focal) and tolerance of peripersonal space—offers fast, physiology-grounded ways to regulate autonomic arousal and improve motor control, providing clinicians practical tools for anxiety modulation, attention, and movement quality in therapy and performance settings.
Actionable Takeaway
Have patients alternate 60–90 seconds of panoramic, soft-gaze awareness (eyes at or slightly below horizon, chin gently tucked) with 60–90 seconds of narrow focus during a 10–15 minute walk or light resistance session, then repeat the same task while varying stance (split/offset), head/eye orientation, and nasal breathing rhythm—observing changes in tension, reactivity, and coordination.
5. The Human Upgrade: Biohacking for Longevity & Performance
Why 18-Year-Olds Wake Up Fresh (And You Don’t) : 1410
Published: 2026-02-05
URL: Listen Here
Summary
This episode focuses on stem cell decline as a driver of aging and disease, contrasting endogenous stem cell mobilization (cumulative, arterial delivery) with IV stem cell infusions (limited by pulmonary first-pass). The guests outline how stem cells coordinate tissue repair, reduce fibrosis, and why stacking microcirculation, mitochondrial, and inflammation-modulating strategies with stem cell support may enhance longevity and recovery. Note: The discussion includes promotional content for a commercial stem cell–mobilizing supplement; cited evidence in the episode is limited and should be interpreted alongside peer‑reviewed research.
Key Takeaways
Stem cell decline (often called stem cell exhaustion) is a core hallmark of aging: red bone marrow converts to fatty marrow with age, lowering the number and effectiveness of circulating stem cells and impairing tissue repair.
Prolonged fasting (about 72 hours) is currently the most evidence-backed, low-cost intervention to rejuvenate stem cells via autophagy; doing this a couple of times per year may support the body’s repair capacity.
Endogenous stem cell mobilization (e.g., via certain plant extracts) can roughly double circulating stem cells (~10 million in a typical 50-year-old) and, when done repeatedly, yields cumulative repair benefits; by contrast, IV stem cells face a pulmonary first-pass effect with only ~20% surviving to circulate.
Stem cells orchestrate repair via exosomes/cytokines—calming inflammation, guiding immune activity, and rebuilding tissue architecture—which can reduce fibrosis/scar formation and improve post-surgical and injury recovery; stacking strategies include enhancing microcirculation, mitochondrial biogenesis, healthy membrane lipids, and targeted inflammation control.
Circulating stem cell count may become a key resilience and longevity marker; elevated systemic inflammation (e.g., CRP, NLRP3-related cytokines) may reflect insufficient endogenous repair rather than a primary target to suppress.
Clinical Insight
Reframing chronic, systemic inflammation as a signal of inadequate endogenous repair—and prioritizing strategies that maintain or restore circulating stem cell availability (e.g., 72-hour fasting, targeted mobilization, microcirculation and mitochondrial support)—can improve recovery quality, reduce fibrosis, and potentially slow age-related decline.
Actionable Takeaway
Recommend a medically supervised 72-hour fast twice per year to induce autophagy and hematopoietic stem-cell regeneration, thereby bolstering the body’s intrinsic repair capacity.
6. The Human Upgrade: Biohacking for Longevity & Performance
Biohackers in the Epstein Files, Generic GLP-1s, Continuous Ketone Monitors, and more... : 1411
Published: 2026-02-06
URL: Listen Here
Summary
This episode spotlights trust in health information, translational aging science (partial reprogramming for vision), next-gen metabolic tracking (continuous ketones), emerging neural interface technologies, and the economic impact of potential generic semaglutide. Clinically, it underscores pairing GLP-1 therapy with strength and nutrition strategies, safeguarding data privacy, and maintaining a cautious, evidence-oriented approach to rapidly evolving biohacking tools.
Key Takeaways
Do not rely on a single authority in longevity/health; diversify information sources, cross-check claims, and consult primary research.
FDA-cleared, first-in-human testing of an eye-targeted gene therapy using three Yamanaka factors marks a milestone for partial epigenetic reprogramming in people with optic nerve damage (safety-focused early trial).
Continuous ketone monitoring—potentially via dual glucose–ketone wearables—may enable real-time metabolic self-experiments for diabetes management and ketogenic/fasting users; protect data privacy.
Microscale wireless brain implants and noninvasive circuit-level neuromodulation signal a shift from molecule-targeting to network-tuning in brain health; strong ethics, consent, and privacy protections are essential.
India’s move toward generic semaglutide could expand GLP-1 access and lower cost globally; clinicians should pair GLP-1 therapy with resistance training and adequate protein to minimize lean mass loss.
Clinical Insight
As GLP-1 agonists become more accessible, preserving lean mass is critical—counsel patients to integrate structured resistance training and adequate protein intake with pharmacotherapy, and monitor body composition over time.
Actionable Takeaway
For patients on GLP-1 therapy, establish a muscle-preservation protocol: obtain baseline and 3–6 month body composition (DEXA or multifrequency BIA), target 1.2–1.6 g/kg/day protein (adjust for renal status), and program 2–3 weekly resistance sessions emphasizing progressive overload.
7. This Week in Cardiology
Feb 06 2026 This Week in Cardiology
Published: 2026-02-06
URL: Listen Here
Summary
This episode critiques the new PREVENT risk score’s performance in young adults—especially its underestimation of risk in non-Hispanic Black patients—reviews an oral PCSK9 inhibitor that robustly lowers LDL-C, highlights positive OCEANIC-STROKE results for a Factor XI inhibitor added to antiplatelets, and re-examines statin safety in light of large RCT data and nocebo effects. It also contextualizes prevention amid major declines in CAD/AMI mortality driven by acute care advances, advocating nuanced, preference-sensitive decisions over rigid thresholds. Limitations: OCEANIC-STROKE results were presented at a conference (no peer-reviewed paper yet); the oral PCSK9 trial reports lipid lowering (a surrogate) without outcomes; pricing/coverage for new agents remain unknown.
Key Takeaways
PREVENT equations substantially underpredicted 10-year CVD risk in non-Hispanic Black adults aged 30–39 (≈46% underestimation), and adding a social determinants index did not correct this, raising concern for algorithmic unfairness and undertreatment.
An oral PCSK9 inhibitor (enlicitide) in the CORALreef Lipids trial reduced LDL-C by about 55% over 52 weeks on top of statins with no safety signal; outcomes data are pending and cost may be a major barrier.
OCEANIC-STROKE: the Factor XI inhibitor (asundexian) added to antiplatelet therapy after non-cardioembolic stroke/high-risk TIA reduced recurrent ischemic stroke by 26% (HR 0.74) with similar major bleeding, with consistent benefit across subgroups.
A large CTT Collaboration meta-analysis of 66 statin RCTs (≈123,000 participants) found no excess risk for 62 of 66 alleged adverse events; small increases in LFT abnormalities, proteinuria, and edema were statistically significant but likely not clinically meaningful; SAMSON supports a strong nocebo effect in perceived statin intolerance.
CAD/AMI mortality and hospitalizations have markedly declined over recent decades—likely driven heavily by advances in acute MI care—complicating the interpretation of small absolute risk differences in primary prevention and arguing against rigid threshold-based decisions.
Clinical Insight
Race-neutral PREVENT risk estimates can substantially underestimate risk in young non-Hispanic Black adults, so reliance on PREVENT thresholds alone may lead to undertreatment; clinicians should integrate clinical judgment and additional risk markers when making preventive therapy decisions in this population.
Actionable Takeaway
For non-Hispanic Black adults under 40 with borderline PREVENT estimates, reassess risk using multiple inputs (family history, BP, LDL, CKD, pregnancy history, smoking, and consider CAC scoring when appropriate) and discuss earlier initiation of statins and/or antihypertensives rather than deferring solely because PREVENT is below a numeric threshold; document shared decision-making.
8. The Human Upgrade: Biohacking for Longevity & Performance
Why Your Muscles Break Down After 40 (Do This To Reverse It) : 1412
Published: 2026-02-08
URL: Listen Here
Summary
This episode argues that impaired mitophagy underlies post‑40 muscle decline and highlights urolithin A—specifically the Mitopure formulation—as a means to reactivate mitophagy and improve muscle function. It promotes pairing supplementation with resistance training, sufficient protein, and sleep to restore strength and energy. Several quantitative claims are presented without direct citations, and the episode includes paid product endorsements, warranting critical appraisal.
Key Takeaways
Age-related declines in mitochondrial quality control (mitophagy) contribute to reduced muscle energy and strength after ~40; restoring mitophagy is framed as central to maintaining muscle function.
Urolithin A is presented as a direct mitophagy activator; only ~30–40% of people produce it endogenously from foods (e.g., pomegranate) due to gut microbiome variability.
A branded, clinically tested urolithin A supplement (Mitopure) is claimed to increase mitochondrial renewal by ~40% after 16 weeks and improve muscle strength by ~12% over four months in middle‑aged adults.
Combining urolithin A with twice‑weekly resistance training, adequate protein intake, and sufficient sleep is emphasized as a practical framework to regain strength and energy.
The episode contains paid endorsements and product-specific claims; detailed citations for several statistics (e.g., cohort size/duration, effect sizes) are not provided in the transcript.
Clinical Insight
Targeting mitochondrial health—particularly by enhancing mitophagy—may help mitigate age-related declines in muscle function; urolithin A shows early human evidence of benefit and could be considered as an adjunct to foundational interventions (resistance training, protein adequacy, and sleep) while recognizing potential conflicts of interest and the need for independent replication.
Actionable Takeaway
For adults over 40, implement a 12–16‑week plan of resistance training at least twice weekly (≈30–45 minutes/session), ensure adequate daily protein (about 1.0–1.2 g/kg/day as a practical target unless contraindicated), and optimize sleep; discuss urolithin A supplementation as an optional adjunct, reviewing existing evidence, product provenance, costs, and patient-specific risks before recommending a monitored trial.
9. THE PRO-AGING PODCAST
S4E1: Peptide Revolution (ft. Dr. Jake Deutsch)
Published: 2026-02-08
URL: Listen Here
Summary
This episode outlines how peptide therapies—especially GLP‑1 agonists—fit into evidence‑informed longevity and metabolic care, emphasizing cautious dosing, high‑quality sourcing, and structured monitoring to protect lean mass and overall health. It reviews commonly used agents (GLP‑1s, BPC‑157, GH secretagogues, thymosin derivatives, GHK‑Cu), routes, cycling, and safety pitfalls, while underscoring that many peptides lack robust human data and remain variably regulated. Clinicians should personalize protocols and prioritize foundational lifestyle interventions alongside any peptide strategy.
Key Takeaways
Peptides are short amino-acid chains that act as signaling modulators; they can amplify physiologic pathways with multi-system effects but are potent agents that require medical supervision and thoughtful dosing.
GLP-1–based therapies (e.g., semaglutide, tirzepatide) serve as a foundational peptide strategy for metabolic optimization beyond weight loss (improved insulin sensitivity, inflammation, cardiometabolic markers); use the lowest effective dose and pair with protein intake and resistance training to preserve lean mass and avoid aesthetic/functional downsides of rapid weight loss.
Safe practice emphasizes reputable sourcing and oversight: avoid unsupervised online purchases, oversized ‘stacks,’ or co-mixing agents in one syringe; select the appropriate route (mostly injectable; select topical, troche, or intranasal options) and introduce one agent at a time.
Monitoring is essential: obtain baseline and interval labs (e.g., CMP, CBC, A1c, lipids, thyroid; IGF‑1 if using GH secretagogues), track body composition monthly (not just scale weight), consider wearables/CGM, and cycle GH secretagogues to reduce receptor downregulation.
Popular non–GLP-1 options discussed include BPC‑157 and thymosin derivatives (for healing/inflammation) and topical GHK‑Cu for skin/hair; many such peptides are not FDA‑approved and human data remain limited—so risk–benefit, regulation, and quality control must guide use.
Clinical Insight
For longevity and metabolic care, GLP‑1 agonists can be a clinically sound anchor, but outcomes and safety depend on preserving lean mass and individualized, monitored dosing—not on broad, unsupervised multi‑peptide ‘stacks.’
Actionable Takeaway
Before initiating peptides (e.g., GLP‑1 or GH secretagogues), set a protocol: obtain baseline labs (CBC, CMP, A1c, fasting lipids, TSH; add IGF‑1 if using GH secretagogues) and body composition (DEXA or InBody), implement a protein and resistance‑training plan, start one agent at the lowest effective dose from a reputable pharmacy, avoid mixing preparations in the same syringe, reassess body composition monthly and labs at 8–12 weeks, and adjust/cycle therapy based on objective data.
10. Huberman Lab
How Genes Shape Your Risk Taking & Morals | Dr. Kathryn Paige Harden
Published: 2026-02-09
URL: Listen Here
Summary
This episode explores how genes and environments jointly shape risk-taking, addiction, aggression, and moral judgment from fetal development through adolescence, emphasizing that many ‘vice’ behaviors share a common, neurodevelopmental genetic substrate. It argues for forward-looking accountability—favoring reward-based behavior change and safety-focused boundaries over retributive punishment—and outlines sex differences in developmental timing, the role of puberty and epigenetics, and the limited clinical utility (to date) of polygenic scores for individuals. Note: The transcript is partial and conversational; specific study details (e.g., sample sizes, effect sizes) were not always provided.
Key Takeaways
Addiction, impulsive aggression, and risky sexual behavior share a broad, highly polygenic architecture whose variants are most active during mid–late fetal cortical development, likely shaping excitation–inhibition balance (GABA/glutamate); thus, substance use and conduct disorders should be viewed as neurodevelopmental conditions.
Pubertal timing and tempo matter: earlier puberty in girls and rapid pubertal tempo in boys associate with higher risks for mental and physical health problems and with signatures of accelerated biological aging on DNA methylation ‘clocks.’
Sex differences are largely mean-level, not etiologic: males show higher rates of externalizing and slower maturation of inhibitory control, yet the underlying genetic liabilities are similar in females; girls more often express aggression relationally, and early-onset conduct problems with callous–unemotional traits (especially in boys) predict poor adult outcomes.
Nature and nurture are tightly interwoven: family, adoption, and registry studies show cross-trait familial transmission (e.g., addiction, antisociality, risky sex); trauma and environment interact with genetic liability. Polygenic scores have limited individual-level predictive power; practical risk counseling still leans heavily on detailed family history and observed temperament.
Accountability should emphasize forward-looking change over retribution: reward-based strategies reliably outperform harsh punishment for shaping behavior (in children, patients, and justice systems). Humans show neural reward responses when wrongdoers are punished, reflecting a cultural pull toward punitiveness; effective systems set boundaries (“penalty box”) to protect others while prioritizing behavior change and reintegration.
Clinical Insight
Externalizing syndromes (substance use disorders, conduct problems with impulsive aggression) are best conceptualized as neurodevelopmental, with shared polygenic underpinnings expressed during fetal brain development and later shaped by puberty and environment—so early identification and reinforcement-based, non-punitive interventions are essential.
Actionable Takeaway
Screen adolescents for early-onset conduct problems and callous–unemotional traits and, when present, counsel families to prioritize consistent boundaries plus positive reinforcement (over harsh punishment); incorporate detailed family history of addiction/externalizing into anticipatory guidance about substances and peer context, and avoid overinterpreting polygenic risk scores for individual prognosis.
Stay connected with Dr Onyx MD PhD for clinical insights and wellness tools that bridge science and everyday care:
Instagram ✦ X (Twitter) ✦ LinkedIn ✦ Website
From Insights to Action
Knowledge without execution changes nothing. The insights above only reach their full potential when integrated into a strategic, personalized plan. That’s where two offerings come in:
Personalized Medical AI Chatbot
Healthcare complexity is overwhelming. Clinical studies, conflicting guidelines, and fragmented records leave most patients paralyzed.
Deploy your Dr Onyx MD PhD Medical AI Chatbot—a personalized architecture that synthesizes your medical history, the latest research, and your unique condition into clear, actionable insights.
It’s not a replacement for your doctors—it’s your secret weapon for making better decisions and becoming the CEO of your own care.
👉 Deploy your Medical AI Chatbot today and take control of your health narrative
Premium Longevity Program
For people who know their most valuable asset is their health.
This year-long partnership delivers clarity, accountability, and physician-led execution. Stop collecting fragmented data and start acting on a ranked, strategic plan tailored to your biology and lifestyle.
👉 Discover the Premium Longevity Program and secure your health as your ultimate investment.